| Title: | A three-dose mRNA COVID-19 vaccine regime produces both suitable immunogenicity and satisfactory efficacy in patients with solid cancers |
|---|
| Authors: | ID Janžič, Urška, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Author)
ID Bidovec, Urška, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Author)
ID Korošec, Peter, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Author)
ID Mohorčič, Katja, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Author)
ID Mrak, Loredana (Author)
ID Čakš, Marina (Author)
ID Ravnik, Maja (Author)
ID Škof, Erik, Onkološki inštitut (Author)
ID Rijavec, Matija, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Author) |
|---|
| Files: |  URL - Source URL, visit https://www.mdpi.com/2076-393X/11/6/1017
 PDF - Presentation file, download (1,55 MB)
MD5: 40ACF11CB9D3946987B74CDC42E116B1
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
|---|
| Abstract: | Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (p < 0.0001). After the booster third dose, anti-SARS-CoV-2 S1 IgG levels were comparable to healthy controls (p = 0.113). There was a decline in Ab levels 3 (p = 0.0003) and 6 months (p < 0.0001) post-third booster dose. No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infection after the third booster dose. Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course. |
|---|
| Keywords: | solid cancer, COVID-19 vaccination, booster third dose |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Submitted for review: | 01.04.2023 |
|---|
| Article acceptance date: | 22.05.2023 |
|---|
| Publication date: | 23.05.2023 |
|---|
| Publisher: | MDPI AG, 2013- |
|---|
| Year of publishing: | 2023 |
|---|
| Number of pages: | Str. 1-12 |
|---|
| Numbering: | Vol. 11, iss. 6 |
|---|
| Source: | Vaccines |
|---|
| PID: | 20.500.12556/DiRROS-27793  |
|---|
| UDC: | 616-006 |
|---|
| ISSN on article: | 2076-393X |
|---|
| DOI: | 10.3390/vaccines11061017 |
|---|
| COBISS.SI-ID: | 153238275 |
|---|
| Copyright: | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 24. 5. 2023;
|
|---|
| Publication date in DiRROS: | 25.02.2026 |
|---|
| Views: | 143 |
|---|
| Downloads: | 55 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
